Lilly's Liver Case: A Closer Look at Analyst Reactions
As analysts assess the implications of Lilly's liver case, questions arise about the thoroughness of their evaluations. This discussion highlights key biotech updates, including Cytokinetics' Myqorzo and Johnson & Johnson's IBD therapy.